PIONIERKRAFT raises a high seven-figure amount in Series A financing round from climate tech investor First Imagine!
22.10.2024 08:46:54 CEST | news aktuell GmbH | Press release
Munich, 21 October 2024
Munich-based energy start-up PIONIERKRAFT has raised a high seven-figure amount in its Series A financing round, led by First Imagine!, a European venture capital firm focused on innovative solutions for a sustainable future. With this investment, PIONIERKRAFT will expand its energy-sharing solution for apartment buildings.
"When we founded PIONIERKRAFT in 2019, we saw an opportunity to build a foundation for the energy transition in small and medium-sized apartment buildings," says Andreas Eberhardt, CEO of PIONIERKRAFT. "This funding will help us scale our network of partners and ramp up mass production of our energy-sharing solution."
First Imagine! recognizes PIONIERKRAFT's growth potential and aims to accelerate the renewable energy transition. "Partnering with PIONIERKRAFT allows us to address the large sector of multi-tenant buildings in Germany that has been excluded from rooftop solar installations," says Alexander Starchenko, Managing Partner of First Imagine!.
The financing will also support the launch of PIONIERKRAFTwerk 3.0, setting new benchmarks in performance and ease of use, making the solution even more compelling to landlords and encouraging the decarbonization of Germany's apartment buildings.
PIONIERKRAFT has also welcomed Hartmut Michels, CEO of standata GmbH, to its advisory board. Michels' experience in the housing and energy sector will support the company’s growth and rollout of PIONIERKRAFTwerk. "The PIONIERKRAFTwerk is a big step towards the Home Energy Management System," Michels notes.
The Series A financing round was supported by Quantum Partners, an M&A consultancy based in Munich specializing in corporate finance and growth capital.
Press Contact
PIONIERKRAFT GmbH
Agnes-Pockels-Bogen 1
80992 Munich
Daniela Schwendy
presse@pionierkraft.de
www.pionierkraft.de
Maisberger GmbH
Jennifer Appel/Julia Kirchhoff
Telefon: +49 (0)89 / 41 95 99-77, -55
E-Mail: pionierkraft@maisberger.com
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Vyoma awarded ESA data procurement contract for space-based data on small space debris24.2.2026 10:53:34 CET | Press release
(Munich, February 24th, 2026) Vyoma, a Munich-based company providing Space Domain Awareness (SDA) capabilities, has been selected as the winner of the ESA tender on ”Data Procurement for Space-Based Statistical Data on Small Space Debris Phase 1”, funded via ESA‘s Space Safety Programme (S2P). ESA’s Meteoroid And Space debris Terrestrial Environment Reference (MASTER) model provides a description of the space environment around Earth, supporting satellite designers, operators and others with risk assessments. Currently, there exists a significant temporal and spatial knowledge gap for observations of space debris with sizes smaller than the detection limit of ground-based sensors. Vyoma's Flamingo-1 satellite is ideally positioned to generate the image data ESA is seeking. Flying “in-situ” at an altitude of 510 km, Flamingo-1's instrument can monitor large volumes of space at once. This sensor detects objects at long and short distances and captures small and fast objects reliably, im
Medi-Globe Launches mAI Companion® — the World’s First Real Time AI Assistant for Pancreatic EUS, Co Developed with IHU Strasbourg —Now MDR CE Marked and Available for Clinical Use in Europe24.2.2026 10:00:00 CET | Press release
Rohrdorf (Achenmühle), Germany — February 24, 2026 — Medi-Globe today announced the launch of mAI Companion®, a real-time medical AI solution designed to assist physicians in detecting pancreatic lesions during endoscopic ultrasound (EUS) — addressing one of the deadliest and most difficult-to-detect cancers, where earlier identification can dramatically change patient outcomes.
Grünenthal licenses exclusive Australian rights to Qutenza® to Clinect24.2.2026 08:43:52 CET | Press release
Aachen, Germany & Victoria, Australia, 24 February 2026 – Grünenthal, a global leader in pain management and related diseases, and Clinect Pty Ltd ("Clinect"), an Australian based company focussed on supporting access to unique products, announced today that they have entered into a definitive agreement whereby Clinect will have the exclusive Australian rights to Qutenza®, a topical, non-systemic, non-opioid patch indicated for the management of peripheral neuropathic pain. Under the agreement, Clinect will be responsible for obtaining marketing authorisation for Qutenza® in Australia and, upon approval, marketing and distributing the product in Australia.
Clean energy needs a clean planet: PLAN-B NET ZERO and everwave launch joint initiative20.2.2026 13:26:02 CET | Press release
(Berlin, Germany) A strong start to 2026. PLAN-B NET ZERO enters into a partnership with the Aachen-based environmental scale-up everwave. With the guiding principle ‘1 euro = 1 kilogram of waste’, the partners recovered 10,000 kilograms of waste from rivers in Cambodia at the start of the initiative Around 11 million tonnes of plastic waste enter the oceans every year. Without effective countermeasures, this volume could almost triple by 2040. Studies show that about 80 percent of marine plastic reaches the sea via roughly 1,656 rivers worldwide. To date, everwave has removed more than 2.4 million kilograms of plastic from rivers in Cambodia, Albania, and Thailand. The company uses waste collection boats, barriers, and manual cleanups to stop plastic before it reaches the oceans. At the same time, mobile sorting and recycling solutions return materials efficiently to the circular economy. AI support optimizes collection routes to clean as many waterways as possible in a sustainable wa
Grünenthal’s proprietary NaV 1.8 inhibitor enters clinical development18.2.2026 11:52:51 CET | Press release
Aachen, Germany, 18 February 2026 – Grünenthal announced today that the first healthy volunteers have been enrolled in a Phase I trial of its voltage-gated sodium channel (NaV) 1.8 inhibitor. The orally administered investigational medicine aims to provide a non-opioid therapy option across a range of acute and chronic pain conditions. Full results of the trial are expected in the second half of 2026.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom